newsfilter
← Latest News
GlobeNewswire·

CEPI to co-fund Vaxxinity's pivotal Phase 3 UB-612 heterologous booster trial to combat SARS-CoV-2 variants

OSLO, Norway and DALLAS, April 06, 2022 (GLOBE NEWSWIRE) -- The Coalition for Epidemic Preparedness Innovations (CEPI) and Vaxxinity, Inc. (NASDAQ:VAXX), a US company pioneering the development of a new class of immunotherapeutic vaccines, today announ